- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04923542
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
January 24, 2024 updated by: H. Lee Moffitt Cancer Center and Research Institute
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is designed as a prospective, single-arm, nonrandomized, open-label, phase I/II trial of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib.
Safety will be monitored initially by a 3+3 design.
This will be followed by a phase 2 study to evaluate intracranial progression free survival (PFS).
If unexpected neurologic toxicities are noted, the dose of radiation therapy will be modified.
Study Type
Interventional
Enrollment (Estimated)
31
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kamran A Ahmed, MD
- Phone Number: 813-745-8424
- Email: Kamran.Ahmed@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Michelle DeJesus
- Phone Number: 813-745-6911
- Email: Michelle.DeJesus@moffitt.org
-
Sub-Investigator:
- Peter Forsyth, MD
-
Sub-Investigator:
- Arnold Etame, MD, PhD
-
Sub-Investigator:
- James Liu, MD
-
Sub-Investigator:
- Nam Tran, MD, PhD
-
Sub-Investigator:
- Michael Vogelbaum, MD, PhD
-
Sub-Investigator:
- Hatem Soliman, MD
-
Sub-Investigator:
- Avan Armaghani, MD
-
Sub-Investigator:
- John Arrington, MD
-
Sub-Investigator:
- Ricardo Costa, MD, MSc
-
Sub-Investigator:
- Hung Khong, MD
-
Sub-Investigator:
- Marilin Rosa, MD
-
Sub-Investigator:
- Aixa Soyano Muller, MD
-
Sub-Investigator:
- Daniel Oliver, MD
-
Sub-Investigator:
- Michael Yu, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- HR+ breast cancer to fulfill the requirement of HR+ disease, a breast cancer must express (≥ 1%), by immunohistochemistry (IHC), at least 1 of the hormone receptors (estrogen receptor [ER] or progesterone receptor [PR]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines
- To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines
- ≤ 15 brain metastases eligible for stereotactic radiation
- Able to swallow oral medications
- Willing to comply with all study procedures and available for duration of the study
- Measurable brain disease per RANO-BM criteria that can be measured in at least one dimension as ≥ 0.5 cm for both intact brain metastases and post-operative cavities
- Eligible for SRS to brain metastases or to the post-operative bed following surgical resection
- Maximum diameter of the largest intact brain metastases ≤ 4 cm
- Eastern Cooperative Oncology Group performance status 0 to 2
- A formalin-fixed, paraffin-embedded tumor tissue block or 10 unstained slides of intracranial/extracranial tumor sample (archival or recent) for biomarker evaluation should be made available and submitted to the central lab for correlative studies. If attempts to obtain archival tissue are unsuccessful the patient may be enrolled.
- Individuals with prior SRS/fractioned stereotactic radiotherapy (FSRT) treatment will be allowed if active measurable disease has not previously been treated with radiation therapy
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 7 days of the first dose of abemaciclib
- WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s), and for three weeks following the last dose of abemaciclib
- Adequate organ function as defined in protocol
Exclusion Criteria:
- Presence of leptomeningeal disease
- Prior receipt of whole brain radiation therapy
- Prior receipt of abemaciclib in the setting of brain metastases or in the past 6 months for the treatment of metastatic disease.
- All toxicities attributed to prior anticancer therapy must have been resolved to Grade 1 (NCI CTCAE Version 5) or baseline before administration of study drug(s) other than: a. Toxicities attributed to prior anticancer therapy that either are not expected to resolve and/or result in long-lasting sequelae, such as neuropathy after platinum-based therapy b. Toxicities that are not expected to interfere with study treatment, such as fatigue, alopecia, or grade 2 hematologic toxicity
- Women who are pregnant or breastfeeding
- The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)
- The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment
- The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
- History of prior malignancy within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of >90%), such as but not limited to, non-melanoma skin carcinoma, or stage I endometriod uterine cancer, and others at the discretion of the PI.
- Major surgery or significant traumatic injury that has not been recovered from by 14 days before the initiation of study drug
- Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of first dose of study treatment
- History of allergy or hypersensitivity to any of the study drugs or study drug components
- Prisoners or individuals who are involuntarily incarcerated
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1: Radiation Therapy and Abemaciclib
Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib.
In the phase I portion, safety will be monitored initially by a 3+3 design.
If unexpected neurologic toxicities are noted, the dose of radiation therapy will be modified.
|
Patients will receive single session SRS to intact brain metastases and post-operative cavities.
For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers.
Abemaciclib will be administered at a dose of 150 mg twice daily.
Other Names:
Abemaciclib will be administered with standard of care endocrine therapy.
Endocrine therapy can consist of fulvestrant or an aromatase inhibitor.
Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
Other Names:
|
Experimental: Phase 2: Radiation Therapy and Abemaciclib
Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation at the phase 1 dose to sites of brain metastases or post-operative cavities with continued abemaciclib.
|
Patients will receive single session SRS to intact brain metastases and post-operative cavities.
For intact brain metastases, this will be 15 Gy to lesions between 31-40 mm, 18 Gy to 21- 30 mm, and 24 Gy to lesions measuring ≤ 20 mm.
Abemaciclib is an orally administered selective small-molecule inhibitor of CDK4 and CDK6 that is 14 times more potent against CDK4 than CDK6 in enzymatic assays that is approved for the treatment of advanced or metastatic breast cancers.
Abemaciclib will be administered at a dose of 150 mg twice daily.
Other Names:
Abemaciclib will be administered with standard of care endocrine therapy.
Endocrine therapy can consist of fulvestrant or an aromatase inhibitor.
Dosing of concurrent endocrine therapy with abemaciclib should follow standard dosing and safety guidelines.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracranial Progression Free Survival (PFS)
Time Frame: Up to 12 months
|
Intracranial Progression Free Survival: defined as the time from the date of start of treatment to investigator-determined date of progression or death due to any cause, whichever comes first.
Progression will be determined by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) Criteria.
|
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracranial local brain tumor control
Time Frame: Up to 12 months
|
Intracranial local brain tumor control following SRS and abemaciclib will be determined from irradiated lesions according to RANO-BM criteria.
|
Up to 12 months
|
Intracranial distant brain tumor control
Time Frame: Up to 12 months
|
Intracranial distant brain tumor control following SRS and abemaciclib will determined by the development of new lesions outside of the irradiated area.
|
Up to 12 months
|
Extracranial Progression Free Survival
Time Frame: Up to 12 months
|
Extracranial Progression Free Survival: Time from the date of start of treatment to the investigator determined date of progression (determined by RECIST) or death due to any cause, whichever occurs first.
|
Up to 12 months
|
Overall Survival
Time Frame: Up to 12 months
|
Overall Survival is defined as the time from the start of treatment to death due to any cause.
|
Up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Kamran A Ahmed, MD, Moffitt Cancer Center
- Principal Investigator: Heather Han, MD, Moffitt Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2021
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
June 8, 2021
First Submitted That Met QC Criteria
June 9, 2021
First Posted (Actual)
June 11, 2021
Study Record Updates
Last Update Posted (Actual)
January 25, 2024
Last Update Submitted That Met QC Criteria
January 24, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Breast Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones
Other Study ID Numbers
- MCC-20899
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
British Columbia Cancer AgencyVarian Medical SystemsRecruitingBrain Metastases, AdultCanada
-
IRCCS San RaffaeleRecruitingBrain Metastases, AdultItaly
-
AHS Cancer Control AlbertaRecruitingBrain Metastases, AdultCanada
-
University Health Network, TorontoRecruiting
-
Centre Francois BaclesseGroupement Interrégional de Recherche Clinique et d'Innovation; ANOCEF/IGCNORecruitingHemorrhagic Brain MetastasesFrance
-
Duke UniversityVarian Medical SystemsCompleted
Clinical Trials on Stereotactic Radiosurgery (SRS)
-
Medical College of WisconsinRecruitingBrain MetastasesUnited States
-
Duke UniversityVarian Medical SystemsCompleted
-
University of Texas Southwestern Medical CenterRecruitingBrain Neoplasms, Adult, MalignantUnited States
-
University of UtahRecruiting
-
Northwell HealthCompletedCancer of the OropharynxUnited States
-
Juergen DebusHeidelberg UniversityCompletedAdult Solid Tumor | Brain MetastasesGermany
-
Dr David MathieuCentre de recherche du Centre hospitalier universitaire de Sherbrooke; Université...Recruiting
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
-
Varian, a Siemens Healthineers CompanyRecruitingBrain Metastases | CNS Neoplasm | CNS Disorder, IntracranialUnited States, Australia